NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00102414,Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer,https://clinicaltrials.gov/study/NCT00102414,,COMPLETED,The primary objective of this study is to compare the time to progressive disease in patients treated with gemcitabine plus carboplatin versus carboplatin monotherapy. Patients will have advanced epithelial ovarian cancer and have failed first-line platinum-containing therapy 6 months after treatment discontinuation.,NO,Ovarian Cancer,DRUG: Gemcitabine,Time to progressive disease,Response rate|Duration of response|Survival time|Toxicity|Quality of Life,,AGO Study Group,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,356,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,AGO-OVAR 2.5,1999-09,,2004-11,2005-01-31,,2006-11-14,,
